Unum Therapeutics Appoints Members To SAB
This article was originally published in Scrip
Executive Summary
Unum Therapeutics has appointed oncology researchers Dario Campana, Malcolm Brenner, John Gribben and Crystal L. Mackall to its scientific advisory board (SAB). Campana is Unum's scientific founder and inventor of the company's technology and also serves as professor, department of pediatrics at the National University of Singapore. Brenner is currently the founding director of the center for cell and gene therapy at Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital. Currently Gribben is professor of medical oncology, director of hemato-oncology and director of stem cell transplantation at Saint Bartholomew's Hospital, Queen Mary, University of London School of Medicine. Finally, Mackall is professor of paediatrics and of medicine at Stanford University School of Medicine and also serves as associate director of the Stanford Cancer Institute.